Related Experiment Video
Updated: Mar 13, 2026
02:21
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
1.8K
Management of Recurrent Ischemic Priapism 2014: A Complex Condition with Devastating Consequences
Michael P Hoeh1, Laurence A Levine1
1Department of Urology, Rush University Medical Center, Chicago, IL, USA.
Sexual Medicine Reviews
|March 1, 2015
Summary
Recurrent ischemic priapism (RIP) management lacks clear guidelines. Current treatments show varied efficacy and side effects, necessitating further research for optimal prevention strategies.
Area of Science:
- Urology
- Andrology
- Pharmacology
Background:
- Recurrent ischemic priapism (RIP) management is poorly defined, with limited evidence for most treatment options.
- The rarity of RIP contributes to the lack of robust clinical trial data.
Approach:
- A comprehensive literature review was conducted to evaluate the pathophysiology and management strategies for RIP.
- The review examined various therapeutic options, including ketoconazole, 5-α-reductase inhibitors, hormonal therapies, PDE5 inhibitors, and sympathomimetic agents.
Key Points:
- Several agents like ketoconazole, finasteride, anti-androgens, GnRH agonists, and estrogen have demonstrated efficacy but may cause significant hormonal side effects.
- Phosphodiesterase type 5 (PDE5) inhibitors are generally well-tolerated, though their efficacy in RIP is not well-established.
- Intracavernosal α-agonist therapy can manage acute priapism episodes, while agents like terbutaline, oral α-agonists, digoxin, hydroxyurea, and gabapentin have limited supporting data.
Conclusions:
- An ideal RIP management strategy prioritizes episode prevention with effective, well-tolerated, and cost-effective medications.
- Despite recent advancements, ongoing research and clinical studies are crucial for refining RIP management protocols.
Related Concept Videos
01:26Angina IV: Management
373
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
373
01:27Peripheral Artery Disease III: Interprofessional Care
486
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
486
01:28Acute Coronary Syndrome IV: Interprofessional Care
374
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
374
01:17Pericarditis III: Medical Management
469
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
469
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
678
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
678
01:14Myocarditis III: Medical Management
295
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
295